A new class-action lawsuit alleges CVS Caremark unlawfully changed its coverage for popular GLP-1 drug Zepbound. | A new ...

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...

A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli ...

A class action lawsuit has been filed against CVS Caremark (NYSE:CVS), the pharmacy benefit manager for health insurer Aetna, ...

GLP-1 medications like Ozempic show promise for multiple health conditions, as experts explore microdosing benefits for blood ...

CVS Caremark was sued Wednesday by two health plan participants who say the pharmacy benefit manager wrongly refuses to cover ...

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s ...

CVS Caremark is facing multiple federal lawsuits by patients challenging its decision to remove weight-loss drug Zepbound ...

Novo Nordisk A/S is poised for long-term growth despite job cuts and margin resets. Click here to find out why NVO stock is a ...

ICER’s comparative effectiveness and value review of Wegovy, Zepbound and oral semaglutide finds they are highly effective ...

While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly on weight loss, Novo Nordisk has now countered that result with ...

Dr. Buettner points out that glucagon, which is targeted by the new medication, can raise a person’s heart rate and may ...